Inspire Medical Systems (NYSE:INSP) Lowered to “Hold” Rating by Wells Fargo & Company

Inspire Medical Systems (NYSE:INSP) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other analysts have also weighed in on INSP. Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, October 27th. JPMorgan Chase & Co. lifted their price target on shares of Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a report on Tuesday, December 16th. Evercore reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Inspire Medical Systems in a research report on Thursday, January 22nd. Royal Bank Of Canada cut their target price on shares of Inspire Medical Systems from $90.00 to $68.00 and set a “sector perform” rating on the stock in a report on Thursday. Finally, Mizuho lowered their target price on Inspire Medical Systems from $130.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $110.65.

Inspire Medical Systems Stock Down 12.4%

NYSE:INSP opened at $59.74 on Thursday. The business’s 50 day moving average is $94.42 and its two-hundred day moving average is $91.48. Inspire Medical Systems has a 52 week low of $53.11 and a 52 week high of $197.75. The company has a market cap of $1.74 billion, a PE ratio of 12.00, a P/E/G ratio of 6.88 and a beta of 0.74.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.96. The business had revenue of $269.08 million during the quarter, compared to the consensus estimate of $264.02 million. Inspire Medical Systems had a return on equity of 11.47% and a net margin of 15.95%.The business’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 EPS. As a group, sell-side analysts expect that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the transaction, the director directly owned 26,046 shares of the company’s stock, valued at $3,320,344.08. The trade was a 7.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Inspire Medical Systems

Hedge funds have recently made changes to their positions in the business. HRT Financial LP grew its holdings in Inspire Medical Systems by 166.5% in the 4th quarter. HRT Financial LP now owns 121,761 shares of the company’s stock worth $11,230,000 after buying an additional 76,080 shares in the last quarter. Brooklyn Investment Group bought a new stake in Inspire Medical Systems during the 4th quarter valued at $307,000. Renaissance Technologies LLC boosted its position in Inspire Medical Systems by 165.0% during the 4th quarter. Renaissance Technologies LLC now owns 410,768 shares of the company’s stock worth $37,885,000 after acquiring an additional 255,768 shares during the period. Counterpoint Mutual Funds LLC grew its stake in shares of Inspire Medical Systems by 30.0% in the fourth quarter. Counterpoint Mutual Funds LLC now owns 5,488 shares of the company’s stock worth $506,000 after purchasing an additional 1,267 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of Inspire Medical Systems in the fourth quarter worth $222,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 results beat and operational strength — Inspire posted $269.1M in Q4 revenue (↑12% y/y) and adjusted EPS of $1.65, topping estimates; gross margin expanded and operating cash flow and buybacks support cash returns. Earnings Release
• Neutral Sentiment: Full earnings package and call are available for deeper read — slide deck and transcript provide detail on assumptions behind the 2026 outlook and tax/adjustment impacts for modeling. Slide Deck / Press Release Call Transcript
• Negative Sentiment: Guidance cut and coding/reimbursement uncertainty — management narrowed FY2026 revenue to $950M–$1.0B and said the Inspire V procedure will likely transition to CPT 64582 with a -52 modifier, potentially lowering physician reimbursement and pressuring procedure volumes. That guidance revision is the primary driver of the selloff. MSN: Revenue Outlook & Coding
• Negative Sentiment: Immediate market reaction — analysts and headlines highlighted the coding/guidance risk and shares fell sharply despite the beat. Zacks: Stock Falls Despite Q4 Beat Investing.com: Shares Slide
• Negative Sentiment: Analyst price-target resets — multiple firms lowered targets (Jefferies to $66, Truist to $70, Mizuho to $85, Piper Sandler to $85) which increases near-term downside pressure even when some ratings remain constructive. Benzinga: Analyst Actions The Fly: Mizuho PT Cut
• Negative Sentiment: Bearish analysis and investor concerns — independent commentary highlights lingering risks around reimbursement, growth cadence and margin sustainability, reinforcing the negative sentiment. Seeking Alpha: Critical Take

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.